RxDoctor Payments Data

Martin Wenthe, MD

Family Medicine · Fresno, CANPI 1063453827

Payments from drug & device makers

$10,971in general payments, 2019–2025

Across 667 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Amgen$1K
  • Pfizer$917
  • Lilly USA, LLC$587
  • Novo Nordisk$437
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$10,90299%
  • Education$691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,971 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$186,808
Medicare patients
566
Services billed
21,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$93,838
MounjaroTirzepatide58$70,175
EliquisApixaban48$49,184
JardianceEmpagliflozin43$45,302
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$38,844
FarxigaDapagliflozin Propanediol34$31,952
TrulicityDulaglutide11$31,746
JanuviaSitagliptin Phosphate28$30,680
Xtampza ErOxycodone Myristate11$27,361
MyrbetriqMirabegron32$25,157
XareltoRivaroxaban15$23,150
Repatha SureclickEvolocumab16$17,488
InvokanaCanagliflozin15$12,117
VascepaIcosapent Ethyl17$10,972
PremarinEstrogens, Conjugated15$8,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$587$101,92169 claims
Novo NordiskOzempic$437$93,83881 claims
PfizerEliquis, Premarin$917$57,75663 claims
Boehringer IngelheimJardiance$202$45,30243 claims
GSKTrelegy Ellipta$269$38,84445 claims
AstraZenecaFarxiga, Symbicort$1,520$36,85647 claims
Johnson & JohnsonXarelto, Invokana$50$35,26630 claims
MerckJanuvia$94$30,68028 claims
Astellas Pharma US IncMyrbetriq$381$25,15732 claims
AbbVieSynthroid$1,292$4,88651 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →